Pfizer, GSK, Denounce India's CL Moves As High Court Ruling Awaited
This article was originally published in PharmAsia News
Executive Summary
Pfizer, GlaxoSmithKline and other global drug makers accuse India of violating international law with its compulsory-licensing policy and damaging MNC profits for the sake of its generics makers.